HALEON Pharmaceuticals: Major
Health Technology
Mkt Cap
92.9B
P/E (TTM)
14.19
EPS
54.45
ROE
50.11%
Div Yield
3.78%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 43.11B | 37.21B | 31.61B | 27.51B | 24.16B | |
| Cost of Goods Sold | -27.02B | -24.98B | -25.39B | -22.84B | -17.71B | |
| Gross Profit | 16.09B | 12.22B | 6.22B | 4.67B | 6.45B | |
| SG&A Expenses | -5.85B | -5.35B | -4.67B | -3.65B | -3.63B | |
| Depreciation | -610.09M | -538.51M | -433.01M | -332.72M | -301.24M | |
| Other Operating Expense | -205.43M | -101.17M | -3.85M | 11.36M | -42.11M | |
| Total Operating Expense | -33.07B | -30.43B | -30.07B | -26.48B | -21.39B | |
| Operating Income (EBIT) | 10.03B | 6.78B | 1.54B | 1.03B | 2.77B | |
| Interest Income | 718.89M | 1.01B | 526.23M | 260.24M | 191.95M | |
| Interest Expense | -50.25M | -51.46M | -37.81M | -6.84M | -2.10M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | -75.25M | -104.21M | -192.30M | -302.77M | 94.67M | |
| Total Non-Operating Income | 593.40M | 852.48M | 296.11M | -39.27M | 243.05M | |
| Pre-Tax Income | 10.63B | 7.63B | 1.84B | 992.79M | 3.02B | |
| Income Tax | -4.25B | -3.05B | -843.46M | -667.38M | -881.77M | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |
| Net Income | 6.37B | 4.58B | 995.59M | 325.41M | 2.13B | |
| EBITDA | 10.64B | 7.32B | 1.98B | 1.36B | 3.07B | |
| EPS (Basic) | 54.45 | 39.11 | 8.51 | 2.78 | 18.23 | |
| EPS (Diluted) | 54.45 | 39.11 | 8.51 | 2.78 | 18.23 | |
| Gross Margin | 37.33% | 32.86% | 19.67% | 16.98% | 26.69% | |
| Operating Margin | 23.28% | 18.22% | 4.88% | 3.75% | 11.48% | |
| EBITDA Margin | 24.69% | 19.67% | 6.25% | 4.96% | 12.72% | |
| Pre-Tax Margin | 24.65% | 20.51% | 5.82% | 3.61% | 12.48% | |
| Net Margin | 14.78% | 12.31% | 3.15% | 1.18% | 8.83% |